A Phase 2 interventional study of Fluticasone Furoate and Fluticasone Furoate/Vilanterol in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 33rd largest by enrollment, is one of 4 that started in 2011, is one of 12 in phase 2, and was the 21st registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 5 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 187th largest by enrollment of the 238 interventional ones that give a count, is one of 14 that started in 2011, is one of 59 in phase 2, and was the 133rd registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma.
This study will investigate the safety and tolerability, pharmacokinetics, and pharmacodynamics of fluticasone furoate/vilanterol (FF/VI) 100/25mcg administered using the novel dry powder inhaler in children aged 5 to 11 years with persistent asthma. Fluticasone furoate (FF, GW685698) is a novel once daily inhaled corticosteroid (ICS) and vilanterol (VI, GW642444) is an inhaled once daily long-acting beta2 agonist (LABA). FF/VI is a novel ICS/LABA combination with once-daily dosing being developed for the treatment of asthma in adults, adolescents, and children of 5 years and above.
This study will be a randomized, double-blind, repeat dose, two period crossover study, with FF as the control. During each of two treatment periods subjects will receive either FF/VI 100/25 micrograms (mcg) or FF 100 mcg daily on 14 consecutive mornings via the novel dry powder inhaler. Approximately 26 subjects will be recruited into this study, with a target of 20 completed subjects. Safety, tolerability, pharmacokinetics and glucose , potassium and cortisol levels will be investigated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
Drug: Fluticasone Furoate
One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
Drug: Fluticasone Furoate/Vilanterol
100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Also known as: FF
Drug pages: Fluticasone furoate · Vilanterol
100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
Also known as: FF/VI
Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.
Time frame: From the start of study medication until Week 11 (Visit 9)/Early Withdrawal
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelet, and White Blood Cell Count Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Reticulocyte and Red Blood Cell (RBC) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Hematocrit Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), and Gamma Glutamyl Transferase (GGT) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Albumin and Total Protein Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Calcium, Chloride, Carbon Dioxide (CO2) Content/Bicarbonate, Glucose, Potassium, Sodium, and Urea/Blood Urea Nitrogen (BUN) Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Total Bilirubin, Direct Bilirubin, Creatinine, and Uric Acid Values at Day 14 of the Respective Treatment Period
Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Peak Expiratory Flow on Day 1 and Day 14 of the Respective Treatment Period
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Day 1 and Day 14 of the Respective Treatment Period
SBP and DBP were measured at Day 1 and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Change From Baseline in Heart Rate at Day1 and Day 14 of the Respective Treatment Period
Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Maximum QTcF at Day 1 and Day 14 of the Respective Treatment Period
QTcF is the QT domain corrected for heart rate by Fridericia's formula. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
AUC(0-t) and AUC(0-4) of FF on Day 14 of the Respective Treatment Period
Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the PK Population.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Cmax of FF on Day 14 of the Respective Treatment Period
Cmax is defined as the maximum observed concentration of FF on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Tmax and Tlast of FF on Day 14 of the Respective Treatment Period
tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
AUC(0-t) and AUC(0-4) of VI on Day 14 of the Respective Treatment Period
Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the VI PK Population.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Cmax of VI on Day 14 of the Respective Treatment Period
Cmax is defined as the maximum observed concentration of VI on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Tmax and Tlast of VI on Day 1 of the Respective Treatment Period
tmax is defined as the time to reach the observed maximum VI concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Blood Glucose and Potassium Values on Day 14 of the Respective Treatment Period
Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Serum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period
SC weighted mean was determined for each participant over the time period of 0-12 hours on Day 14 of the respective treatment period. SC weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 8, and 12 hours (relative to the "0" time point). Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Average Oropharyngeal Cross-sectional Area on Day 1 and Day 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day X)
Distance of Assessment on Day 1 and Day 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Oropharyngeal Volume on Day 1 and Day 14 of the Respective Treatment Period
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Average Flow Rate and Peak Inspiratory Flow Rate (PIFR) on Day 1 and Day 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Inhalation Time on Days 1 and 14 of of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Inhaled Volume on Days 1 and 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Peak Pressure Drop on Days 1 and 14 of the Respective Treatment Period
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.
Time frame: Day 1 and Day 14 of the respective treatment period (up to Study Day 63)
Total Emitted Dose (TED) on Day 14 of the Respective Treatment Period
The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Ex-throat Dose (ETD) and ETD <2 Microns on Day 14 of the Respective Treatment Period
The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.
Time frame: Day 14 of the respective treatment period (up to Study Day 63)
Participants were enrolled into one of two cohorts based upon age; the younger cohort was enrolled after a review of the safety/pharmacokinetic data of at least six participants from the older cohort. Each participant was assigned to treatment randomly; assignment was not to be influenced by whether participants were in Cohort 1 or Cohort 2.
| Milestone | FF 100 µg/VI 25 µg in TP 1 and FF 100 µg in TP 2 | FF 100 µg in TP 1 and FF 100 µg/VI 25 µg in TP 2 |
|---|---|---|
| Started | 13 | 13 |
| Completed | 12 | 12 |
| Not completed | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Met protocol-defined stopping criteria | 0 | 1 |
| Milestone | FF 100 µg/VI 25 µg in TP 1 and FF 100 µg in TP 2 | FF 100 µg in TP 1 and FF 100 µg/VI 25 µg in TP 2 |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | FF 100 µg/VI 25 µg in TP 1 and FF 100 µg in TP 2 | FF 100 µg in TP 1 and FF 100 µg/VI 25 µg in TP 2 |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 11 |
| Not completed | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.
| Participants | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Any AE | 4 | 1 |
| Any SAE | 0 | 0 |
Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelets, and white blood cell (WBC) count at Day 14 of the respective treatment period.
| 10^9 cells per liter (GI/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Basophils, n=21, 23 | 0.025 ± 0.0175 | 0.025 ± 0.0153 |
| Eosinophils, n=21, 23 | 0.296 ± 0.3395 | 0.293 ± 0.3957 |
| Lymphocytes, n=21, 23 | 2.062 ± 0.8462 | 2.339 ± 0.7391 |
| Monocytes, n=21, 23 | 0.244 ± 0.1188 | 0.222 ± 0.1375 |
| Total neutrophils, n=21, 23 | 3.805 ± 2.4090 | 3.106 ± 1.3526 |
| Platelets, n=21, 23 | 270.5 ± 92.27 | 299.0 ± 73.66 |
| WBC count, n=21, 23 | 6.43 ± 2.889 | 5.98 ± 1.897 |
Blood samples were collected for the measurement of hemoglobin and MCHC at Day 14 of the respective treatment period.
| Grams per liter (g/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Hemoglobin, n=21, 23 | 125.9 ± 13.49 | 128.0 ± 6.52 |
| MCHC, n=21, 23 | 330.3 ± 5.83 | 330.8 ± 7.88 |
Blood samples were collected for the measurement of reticulocytes and RBCs at Day 14 of the respective treatment period.
| 10^12 cells per liter (TI/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Reticulocytes, n=21, 23 | 0.07220 ± 0.037473 | 0.07323 ± 0.032203 |
| RBCs, n=21, 23 | 4.33 ± 0.467 | 4.38 ± 0.199 |
Blood samples were collected for the measurement of hematocrit at Day 14 of the respective treatment period. Hematocrit is a measure of the percentage of the volume of the whole blood that is composed of red blood cells, as determined by separation of red blood cells from the plasma (usually by centrifugation).
| proportion of 1 | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Hematocrit Values at Day 14 of the Respective Treatment Period | 0.3816 ± 0.04199 | 0.3866 ± 0.02160 |
Blood samples were collected for the measurement of MCV at Day 14 of the respective treatment period.
| 10^15 femtoliters (fL) per cell | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Mean Corpuscle Volume (MCV) Value at Day 14 of the Respective Treatment Period | 87.9 ± 2.61 | 88.6 ± 3.37 |
Blood samples were collected for the measurement of MCH at Day 14 of the respective treatment period.
| 10^12 picograms (pg) per cell | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Mean Corpuscle Hemoglobin (MCH) Values at Day 14 of the Respective Treatment Period | 29.03 ± 0.941 | 29.25 ± 1.116 |
Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Day 14 of the respective treatment period.
| International units per liter (IU/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| ALT, n=22, 24 | 16.9 ± 14.63 | 17.7 ± 14.88 |
| ALP, n=22, 24 | 278.4 ± 110.01 | 272.6 ± 119.48 |
| AST, n=22, 24 | 28.2 ± 8.38 | 29.0 ± 7.51 |
| GGT, n=22, 24 | 14.6 ± 7.74 | 16.1 ± 10.36 |
Blood samples were collected for the measurement of albumin and total protein at Day 14 of the respective treatment period.
| Grams per liter | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Albumin, n=22, 24 | 45.5 ± 1.97 | 45.6 ± 2.20 |
| Total protein, n=22, 24 | 70.4 ± 2.99 | 70.4 ± 3.12 |
Blood samples were collected for the measurement of calcium, chloride, carbon dioxide content/bicarbonate (CO2/BI), glucose, potassium, sodium, and urea/BUN at Day 14 of the respective treatment period.
| Millimoles per liter (mmol/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Calcium, n=22, 24 | 2.416 ± 0.0591 | 2.415 ± 0.0749 |
| Chloride, n=22, 24 | 103.3 ± 1.75 | 103.8 ± 1.79 |
| CO2 content/bicarbonate, n=22, 24 | 19.0 ± 1.85 | 19.1 ± 2.05 |
| Glucose, n=22, 24 | 4.50 ± 0.689 | 4.53 ± 0.523 |
| Potassium, n=22, 24 | 4.24 ± 0.184 | 4.27 ± 0.265 |
| Sodium, n=22, 24 | 138.6 ± 1.84 | 139.0 ± 1.85 |
| Urea/BUN, n=22, 24 | 4.52 ± 1.006 | 4.52 ± 1.108 |
Blood samples were collected for the measurement of total bilirubin, direct bilirubin, creatinine, and uric acid at Day 14 of the respective treatment period.
| Micromoles per liter (µmol/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Total bilirubin, n=22, 24 | 6.1 ± 1.44 | 5.9 ± 1.72 |
| Direct bilirubin, n=22, 24 | 1.7 ± 0.70 | 1.9 ± 0.41 |
| Creatinine, n=22, 24 | 36.00 ± 7.617 | 37.09 ± 6.225 |
| Uric acid, n=22, 24 | 231.8 ± 64.85 | 233.8 ± 54.04 |
Peak Expiratory Flow (PEF) is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. PEF is calculated as the maximum of three readings taken at each timepoint for each participant. Baseline is defined as the maximum pre-dose measurement at Day 1 for each period.
| liters/minute | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, Baseline, n=25, 25 | 219.0 ± 53.27 | 223.6 ± 56.91 |
| Day 1, 10 minutes post-dose, n=25, 25 | 218.8 ± 53.02 | 223.0 ± 55.15 |
| Day 1, 20 minutes post-dose, n=25, 25 | 222.4 ± 53.50 | 228.2 ± 56.73 |
| Day 1, 1 hour post-dose, n=25, 25 | 223.2 ± 54.23 | 227.2 ± 54.07 |
| Day 1, 2 hours post-dose, n=25, 25 | 227.0 ± 55.94 | 228.6 ± 54.17 |
| Day 14, Pre-dose, n=23, 24 | 224.8 ± 52.86 | 215.0 ± 50.71 |
| Day 14, 20 minutes post-dose, n=23, 24 | 227.2 ± 52.18 | 218.1 ± 52.12 |
| Day 14, 2 hours post-dose, n=23, 24 | 235.7 ± 53.16 | 225.8 ± 48.78 |
| Day 14, 12 hours post-dose, n=23, 24 | 238.9 ± 55.84 | 230.4 ± 52.54 |
SBP and DBP were measured at Day 1 and Day 14 of the respective treatment period. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value.
| Millimeters of mercury (mmHg) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1 SBP, Baseline, n=25, 25 | 97.2 ± 5.41 | 99.9 ± 6.71 |
| Day 1 SBP, 20 minutes, n=25, 25 | -0.1 ± 2.98 | -0.1 ± 4.66 |
| Day 1 SBP, 1 hour, n=25, 25 | 0.5 ± 2.87 | 0.4 ± 3.70 |
| Day 1 SBP, 2 hours, n=25, 25 | 0.9 ± 3.05 | 1.3 ± 2.95 |
| Day 14 SBP, Pre-dose, n=23, 24 | 1.3 ± 4.32 | -1.2 ± 6.92 |
| Day 14 SBP, 20 minutes, n=23, 24 | 1.3 ± 4.61 | -1.2 ± 6.03 |
| Day 14 SBP, 1 hour, n=23, 24 | 1.0 ± 4.42 | -0.8 ± 6.36 |
| Day 14 SBP, 2 hours, n=23, 24 | 1.7 ± 4.17 | -0.8 ± 6.34 |
| Day 14 SBP, 4 hours, n=23, 24 | 2.1 ± 4.22 | 0.1 ± 6.47 |
| Day 14 SBP, 8 hours, n=23, 24 | 2.0 ± 4.33 | -0.4 ± 7.17 |
| Day 1 DBP, Baseline, n=25, 25 | 62.3 ± 3.54 | 63.6 ± 3.86 |
| Day 1 DBP, 20 minutes, n=25, 25 | 0.3 ± 2.81 | -0.3 ± 3.76 |
| Day 1 DBP, 1 hour, n=25, 25 | 1.0 ± 3.17 | 0.8 ± 3.11 |
| Day 1 DBP, 2 hours, n=25, 25 | 0.9 ± 3.42 | 1.0 ± 3.38 |
| Day 14 DBP, Pre-dose, n=23, 24 | 0.6 ± 3.54 | 0.2 ± 3.29 |
| Day 14 DBP, 20 minutes, n=23, 24 | 0.1 ± 3.69 | 0.1 ± 2.62 |
| Day 14 DBP, 1 hour, n=23, 24 | 0.4 ± 4.18 | 0.0 ± 2.30 |
| Day 14 DBP, 2 hours, n=23, 24 | 1.3 ± 3.75 | 0.4 ± 3.19 |
| Day 14 DBP, 4 hours, n=23, 24 | 1.1 ± 4.17 | 1.1 ± 3.35 |
| Day 14 DBP, 8 hours, n=23, 24 | 1.4 ± 3.27 | -0.2 ± 3.02 |
Heart rate (HR) was measured at Day 1 and Day 14 of the respective treatment period. hr=hour. Baseline is defined as the pre-dose measurement at Day 1. Change from Baseline was calculated as the Day 14 value minus the Baseline value. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.
| Beats per minute | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=25, 25 | 84.4 ± 1.63 | 88.6 ± 1.63 |
| Day 14, n=23, 24 | 89.4 ± 1.71 | 85.7 ± 1.67 |
QTcF is the QT domain corrected for heart rate by Fridericia's formula. Treatment, period, day (1 and 14), participant Baseline, period Baseline, and treatment\*day interaction were fitted as fixed effects, and participant was fitted as a random effect.
| milliseconds | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1 QTcF, n=25, 25 | 403.3 ± 1.98 | 402.2 ± 1.98 |
| Day 14 QTcF, n=23, 24 | 404.0 ± 2.06 | 404.2 ± 2.02 |
Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of FF on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the PK Population.
| picograms*hour per milliliter (pg*hr/mL) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| AUC(0-t), n=23, 24 | 38.895 (21.630 to 69.941) | 32.880 (18.268 to 59.179) |
| AUC(0-4), n=17, 15 | 86.14 (70.03 to 105.96) | 83.83 (71.49 to 98.30) |
Cmax is defined as the maximum observed concentration of FF on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
| picograms per milliliter (pg/mL) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Cmax of FF on Day 14 of the Respective Treatment Period | 20.73 (15.16 to 28.36) | 21.16 (14.91 to 30.02) |
tmax is defined as the time to reach the observed maximum concentration, and tlast is defined as the time of the last observed quantifiable concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
| hours | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| tmax, n=20, 19 | 0.965 (0.00 to 2.07) | 0.500 (0.00 to 3.95) |
| tlast, n=20, 19 | 4.030 (0.52 to 4.13) | 4.020 (1.03 to 4.05) |
Area under the concentration-time (AUC) curve from time zero (pre-dose) to the last time AUC(0-t) and from time zero to 4 hours AUC(0-4) of quantifiable concentration of VI on Day 14 of the respective treatment period was measured. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the VI PK Population.
| picograms*hour per milliliter (pg*hr/mL) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| AUC(0-t), n=23 | 44.297 (26.996 to 72.688) | — |
| AUC(0-4), n=11 | 119.19 (102.41 to 138.73) | — |
Cmax is defined as the maximum observed concentration of VI on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
| picograms per milliliter (pg/mL) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Cmax of VI on Day 14 of the Respective Treatment Period | 44.21 (27.65 to 70.70) | — |
tmax is defined as the time to reach the observed maximum VI concentration, and tlast is defined as the time of the last observed quantifiable VI concentration on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose.
| hours | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| tmax, n=21 | 0.170 (0.00 to 2.08) | — |
| tlast, n=21 | 3.870 (0.50 to 4.13) | — |
Blood glucose and potassium values were measured on Day 14 of the respective treatment period. Samples were collected at the following times: pre-dose; 10 minutes (min) and 30 min post-dose; and 1, 2, and 4 hours post-dose. Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.
| Millimoles per liter (mmol/L) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Glucose, n=22, 24 | 5.578 ± 0.1495 | 5.074 ± 0.1443 |
| Potassium, n=21, 23 | 4.059 ± 0.0448 | 4.148 ± 0.0426 |
SC weighted mean was determined for each participant over the time period of 0-12 hours on Day 14 of the respective treatment period. SC weighted mean was derived by dividing the area under the concentration-time curve (AUC; defined as thearea under the concentration-time curve from time zero up to 24 hours) by the sample collection time interval. The sample collection time interval is defined as the difference between the time of the last cortisol sample and the time of the first cortisol sample. Samples were collected at the following time points: 0 (first blood draw/pre-dose); 2, 4, 8, and 12 hours (relative to the "0" time point). Weighted means were derived using the linear trapezoidal rule. Actual relative times were used for the calculation except where actual times were missing. If any actual times were missing, planned relative time were used for these observations. Treatment and period were fitted as fixed effects and participant was fitted as a random effect.
| nanomoles per Liter | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Serum Cortisol (SC) Weighted Mean (0-12 Hours) on Day 14 of the Respective Treatment Period | 193.77 ± 0.069 | 192.50 ± 0.069 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for the study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Pharyngometry data were recorded for each day (Day 1 and Day 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| centimeters squared (cm^2) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=23, 23 | 4.13 ± 2.010 | 3.85 ± 2.043 |
| Day 14, n=23, 23 | 3.76 ± 2.195 | 3.70 ± 2.279 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Distance of assessment is defined as the distance (length measured in centimeters \[cm\]) estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| centimeters (cm) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=23, 23 | 19.20 ± 1.097 | 19.24 ± 0.959 |
| Day 14, n=23, 23 | 19.26 ± 0.717 | 19.10 ± 1.003 |
During the pharyngometry assessment, participants inhaled through a wavetube, which had a mouthpiece with the same dimensions as the mouthpiece on the dry powder inhaler used for this study. This technique was used to measure the size of the throat and mouth (oropharynx) in the form of pharyngograms. Oropharyngeal volume is defined as the volume (cm\^3) of the mouth and throat estimated to be from the lips to the larynx. Pharyngometry data were recorded for each day (Days 1 and 14 of the respective treatment period) using the mean of four measurements (pharyngograms), and the average oropharyngeal cross-sectional area was calculated.
| Liters per minute (L/min) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=23, 23 | 79.49 ± 43.398 | 75.54 ± 44.195 |
| Day 14, n=23, 23 | 72.35 ± 42.437 | 71.47 ± 45.841 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Average flow rate is defined as the average inspiratory flow rate (Liters \[L\]/min) across the inhalation profile when inhaling across the resistance of the inhaler. PIFR is defined as the Peak Inspiratory Flow Rate (L/min) of the inhalation profile when inhaling across the resistance of the inhaler.The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the average flow rate and PIFR were determined.
| Liters per minute (L/min) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, Average flow rate, n=23, 23 | 41.11 ± 11.294 | 42.72 ± 11.593 |
| Day 14, Average flow rate, n=23, 23 | 42.29 ± 10.895 | 41.36 ± 10.354 |
| Day 1, PIFR, n=23, 23 | 65.85 ± 16.649 | 67.60 ± 16.097 |
| Day 14, PIFR, n=23, 23 | 67.36 ± 16.432 | 64.79 ± 15.886 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhalation time is defined as the duration of the inhalation(s) when inhaling across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalation time was determined.
| Seconds (sec) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=23, 23 | 0.97 ± 0.350 | 0.83 ± 0.385 |
| Day 14, n=23, 23 | 0.96 ± 0.314 | 0.91 ± 0.347 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Inhaled volume is defined as the volume of air (Liters) inhaled during the inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was used for each day (Days 1 and 14 of the respective treatment period), and the inhalaled volume was determined.
| Liters | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=23, 23 | 0.69 ± 0.337 | 0.58 ± 0.285 |
| Day 14, n=23, 23 | 0.68 ± 0.308 | 0.65 ± 0.352 |
During the inhalation profile assessment, participants inhaled through a mouthpiece from a device with a similar resistance to the dry powder inhaler used for this study. Peak pressure drop is defined as the maximum pressure drop (kilopascal \[kPa\]) achieved during inhalation across the resistance of the inhaler. The pressure drop during the inhalation was measured, and the inhalation profiles (pressure drop versus time profile) of the participants were obtained. The mean of the two inhalation profile measurements was calculated for each day (Days 1 and 14 of the respective treatment period), and used for subsequent modeling and prediction of dose emission attributes.
| Kilopascal (kpa) | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Day 1, n=23, 23 | 3.79 ± 1.706 | 3.97 ± 1.787 |
| Day 14, n=23, 23 | 3.93 ± 1.877 | 3.67 ± 1.611 |
The total emitted dose (TED) is defined as the mass (micrograms) of the nominal dose that passes beyond the throat. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted total emitted dose.
| micrograms | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Nominal TED FF, n=23, 23 | 87.58 ± 0.305 | 86.33 ± 1.505 |
| Minimum TED FF, n=23, 23 | 87.64 ± 0.330 | 86.72 ± 1.589 |
| Maximum TED FF, n=23, 23 | 87.51 ± 0.289 | 85.93 ± 1.534 |
| Nominal TED VI, n=23, 0 | 20.26 ± 0.162 | NA ± NA |
| Minimum TED VI, n=23, 0 | 20.22 ± 0.153 | NA ± NA |
| Maximum TED VI, n=23, 0 | 20.29 ± 0.175 | NA ± NA |
The ex-throat dose (ETD) and the "nominal ETD" is the mass (micrograms) of active investigational material that passes beyond the throat, nominal being the mean. The recorded inhalation profiles of the participants and the mouth-throat (oropharyngeal) models of the sizes that approximated to pharyngometry measurements of the participants were used in conjunction with the electronic Lung (eLung) for in vitro assessment. The eLung is a breathing simulator that replicates the selected inhalation profile with an active inhaler placed at the lips end of the selected ororpharyngeal model. After the dose is emitted from the inhaler, the analysis and assay of throat deposition and material passing beyond the throat was used to derive the nominal, minimum, and maximum predicted ETD and ETD \<2 microns.
| micrograms | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| Nominal ETD FF, n=23, 23 | 24.96 ± 5.801 | 24.34 ± 8.574 |
| Minimum ETD FF, n=23, 23 | 23.38 ± 7.023 | 22.99 ± 9.120 |
| Maximum ETD FF, n=23, 23 | 26.24 ± 4.825 | 25.48 ± 8.197 |
| ETD <2 microns FF, n=23, 23 | 6.66 ± 0.948 | 5.97 ± 1.382 |
| Minimum ETD <2 microns FF, n=23, 23 | 6.45 ± 0.788 | 5.77 ± 1.319 |
| Maximum ETD <2 microns FF, n=23, 23 | 6.92 ± 1.147 | 6.21 ± 1.476 |
| Nominal ETD VI, n=23, 0 | 8.54 ± 0.953 | NA ± NA |
| Minimum ETD VI, n=23, 0 | 8.33 ± 0.793 | NA ± NA |
| Maximum ETD VI, n=23, 0 | 8.80 ± 1.154 | NA ± NA |
| ETD <2 microns VI, n=23, 0 | 4.86 ± 1.162 | NA ± NA |
| Minimum ETD <2 microns VI, n=23, 0 | 4.60 ± 0.965 | NA ± NA |
| Maximum ETD <2 microns VI, n=23, 0 | 5.18 ± 1.409 | NA ± NA |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FF 100 µg/VI 25 µg | — | 0/25 (0%) | 4/25 (16%) |
| FF 100 µg | — | 0/25 (0%) | 1/25 (4%) |
| Event | FF 100 µg/VI 25 µg | FF 100 µg |
|---|---|---|
| BronchitisInfections and infestations | 1/25 | 0/25 |
| Conjunctivitis viralInfections and infestations | 0/25 | 1/25 |
| Pharyngitis streptococcalInfections and infestations | 1/25 | 0/25 |
| Upper respiratory tract infectionInfections and infestations | 0/25 | 1/25 |
| ConjunctivitisEye disorders | 1/25 | 0/25 |
| HeadacheNervous system disorders | 1/25 | 0/25 |
| Age, Continuous(Years) | FF 100 µg/VI 25 µg and FF 100 µg in TPs 1 and 2 |
|---|---|
| Mean | 8.1 ± 1.97 |
| Gender(Participants) | FF 100 µg/VI 25 µg and FF 100 µg in TPs 1 and 2 |
|---|---|
| Female | 11 |
| Male | 15 |
| Race/Ethnicity, Customized(Participants) | FF 100 µg/VI 25 µg and FF 100 µg in TPs 1 and 2 |
|---|---|
| African American/African Heritage | 3 |
| White - Arabic/North African Heritage | 1 |
| White - White/Caucasian/European Heritage | 21 |
| African American/African Heritage & White | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Oct 2011, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol